Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of Contract - 8-K Filings
On December 1, 2015, Icahn School of Medicine at Mount Sinai ("Mount Sinai") filed a complaint against Neurocrine Biosciences, Inc. ("Neurocrine") in the United States District Court for the Southern District of New York: Icahn School of Medicine at Mount Sinai v. Neurocrine Biosciences, Inc., Case No. 1:15-cv-09414. In the complaint, Mount Sinai alleges that Neurocrine, by entering into an exclusive worldwide collaboration with AbbVie Inc. to develop and commercialize next-generation gonadotropin-releasing hormone, or GnRH, antagonists, has breached its license agreement with Mount Sinai dated August 27, 1999. Mount Sinai is seeking unspecified monetary damages, future sublicensing fees and attorney's fees. Neurocrine believes that it has meritorious defenses to the claims made in the complaint and intends to vigorously defend itself against such claims, but is not able to predict the ultimate outcome of this action.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.